© Copyright 2012 Chemical Biology Ventures Limited. All Rights Reserved. Registered in England & Wales number 7968150. Registered office: 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ. Address for correspondence: 123 Alexander Close, Abingdon, Oxfordshire, OX14 1XD
Preclinical & clinical experience
CBV has experience in preclinical & clinical research in the areas of chemotherapy, chemoprotection, haematopoietic stem cell harvesting & transplantation. This breadth of experience could benefit your programmes.
Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG, Edwards RM. Mobilisation of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha. Blood 85(12) 3412-3415, 1995.
Wark G., Heyworth CM., Spooncer E., Czaplewski L., Francis JM., Dexter TM., Whetton AD. Abl protein kinase abrogates the response of multipotent haematopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha. Oncogene 16(10), 1319-1324, 1998.
Marshall E., Lord BI., Howell AH., Powles R., Hunter MG., Edwards M, Wood LM., Czaplewski LG., Puttick R., Warington S., Boyce M., Testa N., Dexter TM., Lord BI., Millar A. Clinical effects of human MIP�1alpha (LD78) administration to humans: A phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant BB�10010. European Journal of Cancer 34(7), 1023-1029, 1998.
Clemons MJ., Marshall E., Durig J., Watanabe K., Howell A., Miles D., Earl H., Kiernan J., Griffiths A., Towlson K., DeTakats P., Testa NG., Dougal M., Hunter MG., Wood LM., Czaplewski LG., Millar A., Dexter TM., Lord BI. A randomised phase-II study of BB-10010 (Macrophage inflammatory protein-1 alpha with advanced breats cancer receiving 5-FU, adriamycin and cyclophosphamide (FAC) chemotherapy. Blood 92, 1532-1540, 1998.
NMR structure of BB-10010 from Czaplewski et al.
Graphic prepared using PyMol.
The solution structure of the genetically engineered chemokine MIP-1alpha aided design of non-aggregating variants with improved pharmaceutical properties